Randomized controlled trials evaluating low-target oxygen saturation (SpO 2 :85% to 89%) vs high-target SpO 2 (91% to 95%) have shown variable results regarding mortality and morbidity in extremely preterm infants. Because of the variation inherent to the accuracy of pulse oximeters, the unspecified location of probe placement, the intrinsic relationship between SpO 2 and arterial oxygen saturation (SaO 2 ) and between SaO 2 and partial pressure of oxygen (PaO 2 ) (differences in oxygen dissociation curves for fetal and adult hemoglobin), the two comparison groups could have been more similar than dissimilar. The SpO 2 values were in the target range for a shorter period of time than intended due to practical and methodological constraints. So the studies did not truly compare 'target SpO 2 ranges'. In spite of this overlap, some of the studies did find signficant differences in mortality prior to discharge, necrotizing enterocolitis and severe retinopathy of prematurity. These differences could potentially be secondary to time spent beyond the target range (SpO 2 o 85 or 495%) and could be avoided with an intermediate but wider target SpO 2 range (87% to 93%). In conclusion, significant uncertainty persists about the desired target range of SpO 2 in extremely preterm infants. Further studies should focus on studying newer methods of assessing oxygenation and strategies to limit hypoxemia (o 85% SpO 2 ) and hyperoxemia (495% SpO 2 ).
Oxygen therapy in preterm infants must balance the benefits of tissue oxygenation and growth with the risks of oxygen toxicity. 1 Tissue oxygenation and oxygen toxicity depend ultimately on the amount of oxygen delivered to and extracted by the tissues. Oxygen delivery to the tissues depends on the cardiac output, the oxygen content (which in turn depends on the hemoglobin concentration, the oxygen saturation (SpO 2 ) and the partial pressure of dissolved oxygen) and on the position of the oxygen dissociation curve. 2 Oxygen extraction is measured as the difference between arterial and venous oxygen content. 3 Pulse oximetry is now the most commonly used method of monitoring oxygenation. However, the range of optimal saturation by pulse oximetry (SpO 2 ) in preterm infants receiving supplemental oxygen has remained controversial. 4, 5 To identify such a range, five large multicenter, masked, randomized control trials-SUPPORT (Surfactant, Positive Pressure and Pulse Oximetry Randomized Trial), 6 COT (Canadian Oxygen Trial) 7 and three BOOST II (Benefits of Oxygen Saturation Targeting) studies 8, 9 were recently conducted that together enrolled nearly 5000 preterm infants o28 weeks postmenstrual age (PMA) at birth. These studies followed a predetermined design and compared low-target SpO 2 (85% to 89%) with high-target SpO 2 (91% to 95%). The conclusions of these trials, especially those of SUPPORT and BOOST II, have been stated in simple terms as 'maintaining an SpO 2 target of 85% to 89% leads to a lower risk of retinopathy of prematurity (ROP) but a higher risk of mortality'. Because of the reported increased mortality with the lower target range, SUPPORT investigators have been thoroughly criticized by public advocacy agencies and subsequently defended by many neonatologists through expert opinions [10] [11] [12] [13] [14] [15] [16] and a public hearing. 17 These trials were very well planned, designed and executed. However, the methods and interventions used in these trials had physiological, technical and implementation concerns that raise questions about the external validity and practical application of the findings. In this review, we list these concerns and discuss how they weaken the conclusions of the studies, thereby leaving us with a persistent uncertainty regarding the ideal SpO 2 target range and the best way to monitor oxygenation in preterm infants. We group our concerns into two categories:
(a) Problems with the use of pulse oximetry in these studies. (b) Methodological issues.
A. PROBLEMS WITH THE USE OF PULSE OXIMETRY
Problems with using pulse oximetry to determine oxygenation status can arise from several sources:
• The technology used • The location of probe placement • The relationship between SpO 2 and arterial oxygen saturation (SaO 2 ) and • The relationship between SaO 2 and PaO 2 .
deoxyhemoglobin differentially absorb red and near-infrared light. The pulsatile component of red-to-infrared light modulation ratio is calculated. A microprocessor in pulse oximeters has an algorithm that uses this ratio to determine the percentage of hemoglobin bound to oxygen (SpO 2 ) based on a calibration curve generated in healthy volunteers. 18 Are pulse oximeters accurate in preterm infants? Preterm infants have a high concentration (70% to 90%) of fetal hemoglobin (HbF) at birth. 19 Fetal hemoglobin has a fairly similar absorbance pattern compared with that of adult hemoglobin A (HbA) leading to similar functional SpO 2 measurements. [20] [21] [22] In 22 preterm infants, Rajadurai et al. 23 did not observe any significant impact of HbF on SpO 2 measurements. Based on these observations, it appears that the SpO 2 values obtained by pulse oximetry in preterm neonates are similar to that in older children and adults.
How accurate is the Masimo pulse oximeter in neonates? The product manual for Masimo Radical 7 pulse oximeter, 24 which uses signal extraction technology 25 states that the algorithm's accuracy in neonates was established in 79 samples from 16 neonates (neonatal intensive care unit patients-aged 7 to 135 days and weighing between 0.5 and 4.25 kg). Testing was conducted over the SpO 2 range of 70% to 100% with a resultant accuracy of 2.9%. Johnston et al. 26 report that this variation equals ± 1 s.d. So, if the displayed SpO 2 is 88%, true SaO 2 may be in the 85% to 91% range in 68% of the subjects 26 (Figure 1 ) and in the 82% to 94% range in 95% of the subjects. 4 What was the error in the original algorithm in Masimo pulse oximeters? Manufacturers of the pulse oximeter originally generated an algorithm curve referring to SpO 2 in the high range. 26 In 2002, as SpO 2 targets in preterm infants were trending lower, the manufacturers added a lower curve (corresponding to SpO 2 in the 70 to 80-s range- Figure 2b ). The lower curve was free of 'upward adjustment'. 26 The effect of this dual curve was that the SpO 2 values in the region of 87% to 90% (at the junction of the lower and higher algorithm curves, Figure 2b) 26 SpO 2 data gathered from 176 oxygen dependent preterm infants between August 2006 and April 2009 undergoing standard care revealed a lower frequency of SpO 2 readings in the 87% to 90% range than expected. 26 The Masimo Corporation after investigation ascribed the finding to the 'dual curve' in the calibration algorithm used by the oximeter described above ( Figure 2b and Figure 1 . Variables that influence oxygen delivery (based on arterial oxygen content) and oxygen toxicity (based on partial pressure of oxygen (PaO 2 )). This figure illustrates the variation in the arterial oxygen content based on variation in the factors that contribute to it. Each row represents an infant with a specific combination of variables. The oxygen content can vary twofold with a 5% difference in displayed oxygen saturation (SpO 2 ) on the pulse oximeter, and an infant with a lower SpO 2 (88%) can actually have a higher oxygen content than the one with a higher SpO 2 (93%). Infant A has a preductal SpO 2 of 88%, which can correspond to a arterial oxygen saturation (SaO 2 ) range of 85% to 91% in approximately two-thirds of subjects (±3% variation with pulse oximeters). If the corresponding preductal SaO 2 is assumed to be 86%, and she has never received a transfusion, her hemoglobin F (HbF) concentration is 490%. 2, 38 The corresponding preductal PaO 2 is 36 mm Hg. If this infant has a hemoglobin (Hb) concentration of 8 g dl − 1 , her arterial oxygen content will be approximately 9.5 ml dl − 1 . Infant B has a postductal SpO 2 of 88%, which can correspond to a SaO 2 range of 85% to 91% in approximately two-thirds of subjects. If postductal SaO 2 is assumed to be 90%, the corresponding preductal SaO 2 may be 92%. If this baby had received two transfusions, her HbF concentration is approximately 50% 2,38 and the corresponding preductal PaO 2 is 52 mm Hg. If this infant has a Hb concentration of 13 g dl − 1 , her arterial oxygen content will be approximately 16.4 ml dl − 1 . Infant C who has never been transfused with blood and with a preductal pulse oximeter probe that displayed an SpO 2 of 93% and a PaO 2 of 43 mm Hg is at significantly reduced risk of oxygen toxicity compared with infant B in spite of a higher displayed SpO 2 . Infant D has the same displayed SpO 2 as infant C (93%). However, his pulse oximeter is located on his left foot (postductal), and he has received blood transfusions. His PaO 2 is considerably higher (95 mm Hg) compared with infant C (43 mm Hg) putting him at risk for oxygen toxicity. A higher Hb concentration results in higher arterial oxygen content.
black line and hyphenated black line shown by an arrow in Figure 3 ). This lead to an artificial elevation of SpO 2 readings that was maximal at a displayed value of 90% and was around 1.6% higher (2% as only whole numbers are displayed- Figure 3 ). Masimo Corporation supplied a new software with a revised algorithm that relied on a calibration curve with a uniform slope (diagrammatically shown in Figure 2b ). This was installed in all trial oximeters in United Kingdom and Australia (New Zealand had completed enrollment) between December 2008 and May 2009 and in the COT trial between February and June 2009. As pulse oximeters from this manufacturer were used in the SUPPORT trial, it is possible that this discrepancy existed (but was unrecognized). As seen in Figure 3 , the difference in SpO 2 readings between the original algorithm and revised algorithm is minimal. The change in median SpO 2 in COT and BOOST-II trials was ⩽ 1% following revision of the algorithm (Supplementary Figure S1 ).
What was the impact of modification/revision of the pulse oximeter software algorithm? Meta-analysis of mortality data from infants on pulse oximeters with revised software (death at discharge for BOOST II-United Kingdom and Australia-and death before 18 months for COT trial) showed a relative risk of 1.41 (1.14 to 1.74), favoring the high SpO 2 group. 27 The time spent at o85% SpO 2 among patients on supplemental oxygen with revised algorithm was significantly HbF HbA Figure 2 . Infographic showing an overview of reasons for decreased separation between the low-and high-target oxygen saturation (SpO 2 ) arms in SUPPORT, BOOST-II and COT trials. The intended separation between the two groups during periods of oxygen supplementation was 6% (A). The original Masimo algorithm had a steeper slope in the infrared-to-red light modulation ratio curve corresponding to 87% to 90% SpO 2 , resulting in a maximal increase in 2%-point increase in displayed SpO 2 around this range (B). The effect of location of the probe (preductal vs postductal and a gradual increase in hemoglobin A (HbA) with transfusions might have altered the relationship between SpO 2 and partial pressure of oxygen in the retinal (and intestinal) circulation (C). Instability secondary to masking possibly led to a tendency to increase fraction of inspired oxygen (FiO 2 ) in the low-target group and decrease FiO 2 in the high-target group when displayed SpO 2 was in the unstable zone (D-see Figure 3 ). The end result was a lower than intended separation between the two SpO 2 target zones (E). HbF, hemoglobin F; NEC, necrotizing enterocolitis; ROP, retinopathy of prematurity.
higher in the low-target group (21.5%) compared with the hightarget group (10.7%). From a physiological perspective, severe hypoxemia can increase mortality. Therefore, for mortality to increase after revision of the algorithm, one would expect a significant increase in proportion of time spent with severe hypoxemia. The proportion of time spent with SpO 2 o85% decreased slightly in both BOOST-II (United Kingdom/Australia) and COT trials following revision of the algorithm (Supplementary Figure  S1 ) and should have had minimal effect on mortality. The revision of pulse oximeter algorithm did not significantly alter mortality at 18 months in the COT trial (from 17.4% to 16.8% in the lowertarget group and a decrease from 17.9% to 14.1% in the hightarget group). 7 In sharp contrast, mortality before discharge significantly increased in the 85% to 89% SpO 2 target group from 15.6% to 23.1% following revision of the algorithm in BOOST-II trial 9 (Supplementary Figure S1 ). A recent editorial 5 pointed out a puzzling reversal in the direction of the observed treatment effect on mortality at discharge in BOOST-II (United Kingdom) following installation of the revised algorithm (Supplementary Figure S2 ). This increased mortality cannot be explained solely on the basis of shift in displayed SpO 2 .
Although the etiology of increased mortality in the low SpO 2 target arm in BOOST-II is not clear, we offer the following speculations. It is possible that the pulse oximeter algorithm revision had a minimal effect on oxygenation. Intermittent hypoxemia probably had a bigger role in etiology of higher mortality at discharge 28 in the low-target arm 29 (Figure 2e ). The time spent in o 85% SpO 2 in the low-target group in BOOST-II trial was nearly twice the time spent in 495% SpO 2 (24.2% vs 12.5%, respectively, Supplementary Figure S1 ). The time spent in o85% SpO 2 in the low-target group in COT trial was only slightly higher than the time spent 495% SpO 2 (19.3% vs 16.3%, respectively, Supplementary Figure S1 ). This may be secondary to lack of a mandated/standardized low alarm setting in some of the BOOST-II protocols and a protocol-defined limit with monthly feedback to centers in COT. 5 Secondly, the overall incidence of death before discharge was higher in United Kingdom (21.8%) compared with Australia (16.05%) and New Zealand (13.23%) (Supplementary Figure S3 ). There were more infants enrolled in United Kingdom after revision of the pulse oximeter algorithm compared with Australia and New Zealand (New Zealand completed its recruitment prior to algorithm revision). However, even within the BOOST-II Australian subjects, revision of the algorithm increased mortality in the low-target group (Supplementary Figure S2 ) which is difficult to explain from a physiological perspective. Finally, the impact of stopping the BOOST-II United Kingdom and Australian trials early on the validity of the results needs further evaluation. 30, 31 Location of probe placement As preductal oxygen content represents oxygen delivery to the brain, SpO 2 targeting trials should ideally compare preductal SpO 2 s. However, the site of study pulse oximeter probe placement was not specified in these trials. Beyond the first few days of life, the ductus arteriosus is often closed in most patients, and if open, oxygenated blood usually shunts from left to right. In these conditions, in theory, there should not be a significant difference between preductal (right upper extremity) and postductal (lower extremity) SpO 2 values. We recently compared concurrent preductal and postductal SpO 2 values in preterm infants, which were obtained using Masimo pulse oximeters, as part of critical congenital heart disease screening 32 in the neonatal intensive care unit. Based on their clinical status and on follow-up, none of these infants had critical congenital heart disease or an open ductus arteriosus. Among 96 preterm infants born at o 28 weeks gestation, the SpO 2 recording before discharge (at 95 ± 26 days of postnatal age) was identical in the preductal and postductal extremity in 42 (44%) infants. In 36% of preterm infants, postductal SpO 2 was higher than preductal SpO 2 (range 1% to 4% higher). In 20% of infants, preductal SpO 2 was higher than postductal SpO 2 (range 1% to 3%)-(see Supplementary Figure  S4 ). The difference between preductal and postductal SpO 2 may be ⩾ 3% in 10% of and ⩾ 2% in 28% of preterm infants o28 weeks PMA at birth even at the time of discharge. Therefore, it is possible that the lack of specification of the site of probe placement in these five trials may have further contributed to variation in preductal PaO 2 at each displayed SpO 2 level (Figure 1 ).
Relationship between SpO 2 and SaO 2
The standard manufacturers' claim of accuracy of detection of SaO 2 using the SpO 2 measured by pulse oximeters is ± 2% to 3% over the range of 70% to 100% SpO 2 . 33 In addition, sensor misalignment, light interference, 34 arms, respectively, based on the revised algorithm. The display of 88% to 92% to the bedside providers using the revised algorithm corresponded to 85% to 89% in the low arm and 91% to 95% in the high arm (blue and pink bars along the x axis). The instability in displayed SpO 2 between 84% and 88% on the y axis in the low SpO 2 target group possibly led to a tendency to increase fraction of inspired oxygen (FiO 2 ). Similarly, the instability of displayed SpO 2 between 92% and 96% in the high SpO 2 target group might have led to a tendency to decrease FiO 2 . The net effect of the algorithm change and the effect of masking was decreased separation between the two groups (see text for details; modified from BOOST II protocol and reference Schmidt et al. 44 ).
the specification may cause an error in estimation of SpO 2 . 33 Rosychuk et al. 35 reported that umbilical arterial SaO 2 was lower than postductal SpO 2 in preterm infants by − 1.84 (95% CI − 7.6% to 3.9%). In the same study, postductal SpO 2 of 85% to 89% was associated with umbilical arterial SaO 2 o 85% in 39% of samples (and o80% in 10% of samples). In our laboratory, we have prospectively evaluated preductal SaO 2 values from 520 right carotid arterial and mixed venous blood gas samples (from a main pulmonary arterial catheter) in 58 preterm lambs (127 to 134 days gestation, term~147 days) and compared them with concurrently obtained preductal SpO 2 . Preductal SpO 2 of 85% to 89% was associated with a right carotid arterial SaO 2 o85% in 16% of samples (and o 80% in 2%). A significant increase in SaO 2 and mixed venous oxygen saturation (both obtained from a Radiometer blood gas analyzer, Radiometer ABL825, Westlake, OH, USA) was observed with increasing SpO 2 , but there is considerable divergence/discrepancy of these two values in some zones, especially at the extremes of oxygenation (Supplementary Figure S5 and Table 1 ).
Relationship between SpO 2 and PaO 2
Oxygen toxicity and oxygen delivery to the tissues are determined by the local concentration of oxygen in the tissue that in turn depends on PaO 2 , hemoglobin concentration, oxygen content of the blood and blood flow (Figure 1 ). Although SpO 2 and SaO 2 are reasonable surrogate markers for PaO 2 , the relationship between SaO 2 and PaO 2 is asymptotic, and SaO 2 is a poor estimator at high values of PaO 2 . Right carotid arterial and simultaneous mixed venous (pulmonary arterial) PO 2 values from preterm lambs are shown in Supplementary Figure S6 . The arterial values and variability observed in the preterm animal model are similar to that described in preterm neonates. 36 Studies in neonates have shown that monitoring transcutaneous PO 2 results in less time spent with high oxygen tension, time spent with low oxygen tension and less variability in oxygen tension compared with SpO 2 monitoring. 37 A given displayed SpO 2 value may be associated with a wide range of PaO 2 , oxygen content, oxygen delivery and extraction (Figure 1 ). In addition, the type of hemoglobin (adult-HbA vs fetal-HbF) alters the relationship between SaO 2 and PaO 2 (see below). Therefore, even though trials have targeted different ranges of SpO 2 in the two groups, there may have been considerable overlap in the true PaO 2 to which these groups were exposed.
What is the effect of transfusions on PaO 2 -SpO 2 relationship in preterm infants? Emond et al. 19 have demonstrated that extremely preterm infants (26.4 ± 1.4 weeks PMA at birth) have a high concentration of HbF (70% to 90%) and cord blood has a P50 (partial pressure of oxygen at which blood saturation is 50%) of 18.3 ± 1.9 mm Hg. The P90 of cord blood (PO 2 at 90% SpO 2 ) was 40.8 ± 3.6 mm Hg. Following transfusion of packed red blood cells (PRBC-mean volume-26.9 ml kg − 1 ), HbF decreased from 92.9 ± 1.1% to 42.6 ± 5.7% during the first week of postnatal life in extremely preterm infants. This decrease was associated with an increase in P50 from 18.5 ± 0.8 to 21 ± 1 mm Hg. 38 In preterm infants with bonchopulmonary dysplasia at 42.2 ± 4.7 weeks PMA, P50 was 25.1 ± 2.7 mm Hg (similar to an adult value of 26 mm Hg to 27 mm Hg). 39 Hence, transfusions significantly increase the percentage of adult hemoglobin in the blood. A PaO 2 range of 50 mm Hg to 75 mm Hg is associated with SpO 2 of 96% to 97% with HbF and only 85% to 94% with HbA. 40 The presence of HbA markedly increases PaO 2 required to achieve the same SpO 2 and alters the balance between oxygen content/ delivery and oxygen toxicity (Figure 1 -case D). 38 Therefore, in these five trials, PRBC transfusions may have altered oxygen tension and content for a specific SpO 2 range and further contributed to the variability in the SpO 2 -PaO 2 relationship.
Why do the mortality curves of the low SpO 2 target and high target groups separate after the first couple of weeks of postnatal age? With increasing postnatal age, the cumulative total volume of transfused PRBC to preterm infants increases resulting in a high percentage of HbA in the blood. 2, 38 An interesting observation in all the trials is that the difference in mortality between the lowtarget SpO 2 group and high-target group appears after a few weeks of postnatal age. 6, 7, 9 This phenomenon can be explained by a unique, paradoxical relationship between oxygen delivery, arterial PO 2 and fetal hemoglobin. 41 It is often assumed that oxygen delivery is decreased in the presence of HbF because of its increased affinity to oxygen. It is true that when PaO 2 is maintained at a high value, better oxygen delivery would exist if the oxygen dissociation curve is shifted to the right with adult hemoglobin. However, a leftward shift in the hemoglobin-oxygen dissociation curve resulting from high levels of HbF may better maintain oxygen delivery during episodes of severe hypoxemia. 41 Wimberley 42 calculated that during hypoxemia, the infant would achieve better oxygen delivery with fetal oxygen dissociation curve than with an adult curve. In a subgroup of SUPPORT Abbreviations: CaO 2 , arterial oxygen content in ml dl − 1 ; OER, oxygen extraction ratio; PaO 2 , partial pressure of oxygen in the arterial blood; P pa O 2 , mixed venous/main pulmonary arterial partial pressure of oxygen; PVR, pulmonary vascular resistance; Q p , left pulmonary arterial blood flow per kg body weight. OER = (arterial oxygen content − venous oxygen content) × 100/arterial oxygen content. Data are shown as mean ± s.d.; derived from 520 simultaneous right carotid arterial and mixed venous (pulmonary arterial) blood gases. ¶ Po0.01 compared with 85% to 89%; † Po 0.01 compared with 91% to 95%; *Po0.01 compared with 96% to 99%.
Oxygen saturation in preterm S Lakshminrusimha et al patients, such episodes of intermittent hypoxemia (SpO 2 ⩽ 80%) increased in both groups over the first 3 weeks of life followed by a decrease in the high-target group compared with a plateau in the low-target group. 28 In addition, as pointed out by Vento, 1 it may take some time before the consequences of intermittent hypoxemia are translated into clinical vulnerability. The reduced frequency of intermittent hypoxemic episodes and relatively better oxygen delivery due to high fetal hemoglobin levels and lag in manifesting clinical consequences of hypoxemia may explain lack of difference in mortality between the two groups during early postnatal period.
Is there a significant difference in oxygenation between 85% to 89% and 91% to 95% SpO 2 target range? Table 1 shows the difference in various parameters of oxygenation in preterm lambs at ⩽ 84%, 85% to 89%, 91% to 95% and ⩾ 96% SpO 2 . There is a statistically significant increase in PaO 2 , and mixed venous PO 2 with increasing SpO 2 . There was no significant difference in arterial oxygen content or oxygen extraction ratio (OER = arterial oxygen content − venous oxygen content as a percentage of arterial oxygen content) between the 85% to 89% and 91% to 95% SpO 2 groups. However, arterial oxygen content significantly decreased and oxygen extraction significantly increased when SpO 2 decreased o85% ( Table 1) . Pulmonary vascular resistance (PVR) is similar between 91% to 95% and 96% to 99% SpO 2 range. There is a significant increase in PVR in the ⩽ 84% and 85% to 89% groups ( Table 1 and Supplementary Figure  S7) . These results indicate a significant difference in oxygen delivery, extraction and PVR especially during episodes of desaturation o85%. Such intermittent hypoxemic episodes were observed more frequently in the low SpO 2 target group in the SUPPORT trial 28 and time spent o 85% was significantly higher in the low SpO 2 target group in the COT and BOOST-II trials (Supplementary Figure S1 ). We speculate that during periods of SpO 2 o 85%, preterm infants may have suboptimal oxygen delivery to the tissues, increasing the risk of pulmonary hypertension and necrotizing enterocolitis (NEC). This may explain some of the findings of the trials and the meta-analysis. 27 B. METHODOLOGICAL ISSUES How were pulse oximeters altered to mask the target SpO 2 range? To maintain masking, electronically altered pulse oximeters were used that showed saturation levels of 88% to 92% for both targets of SpO 2 , with a maximum variation of 3%. For example, a displayed reading of 90% corresponded to true level of 87% in the group assigned to lower SpO 2 (85% to 89%) and 93% in the group assigned to the higher SpO 2 (90% to 95%). The SpO 2 reading changed and reverted to actual values when it was o84% or 496% in both groups (Figure 3 ). Similar masking was successful in the first BOOST trial. 43 What was the impact of masking algorithm on titration of oxygen therapy? Schmidt et al. 44 reported an interesting observation related to rapidity of change in displayed SpO 2 values secondary to masking 44 and is shown in Figure 3 (modified from Figure 1 in Schmidt et al. 44 and BOOST-II United Kingdom protocol). The masking algorithm achieved a 3% increase (in the low SpO 2 target arm) and a 3% decrease (in the high SpO 2 target arm) in displayed values. The displayed values returned to true values at SpO 2 ⩽ 84 and ⩾ 96% (Figure 3 ). Above 84%, the displayed values began to deviate from true values. Oximeters designed for the lower SpO 2 target rapidly established a +3% display offset as the true SpO 2 increased from 84% to 85%, then maintained this offset until a true SpO 2 of 93%, equivalent to a displayed SpO 2 of 96%. The displayed SpO 2 remained constant at 96% between true SpO 2 values of 93 and 96% as the +3% offset was reversed. When the true saturation decreased from 85 to 84% (1% drop), the displayed SpO 2 decreased from 88 to 84% triggering the lower limit alarm in the process (Figure 3 -zone of instability). Caregivers had a tendency to maintain saturations above this zone of instability by potentially increasing inspired oxygen. The opposite phenomenon occurred in oximeters designed for the higher target group. When true saturations increased from 95% to 96%, displayed SpO 2 jumped from 92% to 96% triggering the higher limit alarm in the higher target group (zone of instability). This may have led to a tendency to decrease inspired oxygen in the higher target group. 44 This differential management reduced the separation between the median true SpO 2 between the two groups ( Figures  2 and 3) . A similar phenomenon has possibly occurred in BOOST-II and SUPPORT trials as well. The net effect is a reduced separation and SpO 2 overlap between the two arms ( Figure 2) .
What is the impact of true separation in SpO 2 obtained between the two groups and morbidity and mortality? As mentioned previously, the meta-analysis of these trials demonstrated increased mortality at discharge, decreased severe ROP and increased NEC in the low-target SpO 2 (85% to 89%) group compared with the high SpO 2 group (91% to 95%). 27 Although a 6% separation in SpO 2 (85% to 89% vs 91% to 95%) was intended between the restricted and liberal oxygen groups while on supplemental oxygen, only 1.54% to 2.67% separation in median SpO 2 was achieved between the groups in these studies. 44 It is interesting and concerning that in spite of poor separation between the two groups, the meta-analysis showed differences in mortality, ROP and NEC. If better separation were achieved between the groups, would the mortality and incidence of NEC be higher in the 85% to 89% target SpO 2 group? Figure 4 is redrawn superimposing the saturation distributions in the intervention and control groups from SUPPORT, COT and BOOST-II trials to illustrate the true difference in saturations. It is difficult to demonstrate a 'dose effect' on mortality, NEC or severe ROP based on SpO 2 achieved while on supplemental oxygen. The COT trial achieved better separation between the two groups, and even here, the majority of infants in the low saturation target group had a median SpO 2~9 0% both in the first 3 days of life and thereafter. The BOOST II separation graphs with the original and the revised algorithm reveal improved separation with the revised algorithm. Tighter compliance, mandated lower displayed SpO 2 alarm limits and wider separation likely reduced exposure to extreme SpO 2 levels more effectively in COT (Supplementary Figure S1 ).
The investigators of COT performed a post hoc subgroup analysis on the effects of targeting higher vs lower SpO 2 , looking at the difference between centers with more or less separation between median SpO 2 and outcomes (presented as an abstract at Pediatric Academic Societies 2014-abstract no. 1400.5 on http:// www.pas-meeting.org/abstracts/default.asp). They found that the overall separation was 2.5% and that, paradoxically, the centers with greater separation observed lower rather than higher rates of death and disability at 18 months in the 85% to 89% group (50% with more separation and 54% with less separation) than the 91% to 95% group (55% with more separation and 44% with less separation), consistent with their previous finding of no significant harm with the lower SpO 2 target. There was no significant difference in death before 18 months with more separation in SpO 2 between the two arms (17% with more separation and 16% with less separation in the 85% to 89% arm and 18% with more separation and 12% with less separation in the 91% to 95% arm). Therefore, better separation between the lower and higher target groups may not increase the difference in mortality between the two groups.
What is the impact of intermittent hypoxemia or hyperoxemia? Di Fiore et al. 28 analyzed data derived from the SUPPORT trial and demonstrated that the lower SpO 2 target range was associated with increased incidence of intermittent hypoxemia. This may be another factor that may alter the risk of poor outcomes in the low oxygenation group if saturation targets were not strictly applied that may represent the reality in many busy neonatal units. Similarly, in the COT trial there was a significant difference in time spent o85% and 495% in both groups 7 (Supplementary Figure S1 ). Decrease in SpO 2 o 85% increases PVR (Supplementary Figure S7 ) and reduces oxygen delivery to tissues and increases oxygen extraction (Table 1) . Obtaining data on time spent o 85% and 495% in individual patients and linking that to outcome may enhance our understanding of differences in outcomes between the two groups.
CONCLUSION
Although these trials had a similar design, there is variation between the trials in the separation of SpO 2 achieved between the two arms and the variable influence of the software algorithm modification in the trials. It is difficult to explain the findings of these five studies using physiological principles of gas exchange and oxygen transport. Multiple factors outlined in this article influence the results of these studies. As pointed out by Bateman and Polin, 29 it is not clear to what extent individuals who experienced death or ROP actually received the intended intervention. It is possible that individual patients who suffered severe ROP or NEC/death spent more time with SpO 2 above or below the intended range or had multiple episodes of brief hyperoxemia or hypoxemia. Better methods of assessing oxygenation, such as simultaneous SpO 2 and tissue SpO 2 by nearinfrared spectroscopy 45 or transcutaneous oxygen tension monitoring 37 may be necessary but are not practical for continuous monitoring. Automated closed-loop control of inspired oxygen based on SpO 2 may enable clinicians to effectively maintain SpO 2 s in the target range. 46 Sola et al. 4 in a recent elegant review have suggested using a wider intermediate target such as 88% to 94% to avoid extremes of hypoxemia and hyperoxemia. The BOOST II trial (United Kingdom and Australia) follow-up results and the planned individual patient data-level meta-analysis of these studies will hopefully shed light on these associations and help us provide the best care for our tiny and most vulnerable patients. Mortality numbers currently available are shown as percentage (%) (note that 18-to 22-month mortality numbers are currently not available for BOOST-II United Kingdom and Australia trials and reflect mortality at discharge). Currently available numbers for the incidence of severe retinopathy of prematurity (ROP) and necrotizing enterocolitis (NEC) are shown. As SUPPORT and original algorithm BOOST-II data are reported using the original algorithm, corresponding SpO 2 numbers on the revised algorithm are shown in gray color. A saturation of 90% in the original algorithm corresponds to a saturation of 88% on the revised algorithm.
